Lexaria Bioscience Corp. (NASDAQ: LEXX) Patented Drug-Delivery Platform Shows Promise in Hypertension Space
Aug 6th, 2021
One of the most pervasive diseases in first-world countries, heart disease is the leading cause of death for men and women of most racial and ethnic groups in the United States, with one person dying every 36 seconds from cardiovascular disease. According to the Centers for Disease Control and Prevention (“CDC”), high blood pressure, or hypertension, is a key risk factor for both heart disease and stroke, and nearly half of all adults in the United States, or 108 million, have hypertension — yet only about 24% of those have their condition under control. Many don’t even know they have it. The urgency of finding effective treatments for this life-threatening disease can’t be understated, with many companies, including Lexaria Bioscience Corp. (NASDAQ: LEXX) (Profile), with its patented DehydraTECH(TM) drug delivery, joining the effort to offer safe, effective and affordable treatments. Hypertension and related conditions are also points of focus for other drug-making juggernauts such as Pfizer Inc. (NYSE: PFE), Merck & Company Inc. (NYSE: MRK), Novartis AG (NYSE: NVS) and AstraZeneca PLC (NASDAQ: AZN).